Acute toxicity of image-guided hypofractionated proton therapy for localized prostate cancer

Nakajima, Kimiko; Iwata, Hiromitsu; Ogino, Hiroyuki; Hattori, Yukiko; Hashimoto, Shingo; Nakanishi, M.; Toshito, T.; Umemoto, Yukihiro; Iwatsuki, Satoshi; Shibamoto, Yuta; Mizoe, Jun‐etsu

doi:10.1007/s10147-017-1209-8

Cited by 29 publications

(35 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Details of the system have been described previously (15,16). Our methods of PT planning and delivery have been described in detail previously (17,18). Prior to PT, patients underwent gold marker implantation near or inside the tumor for target matching and replanning.…”

Section: Methodsmentioning

confidence: 99%

Transient increases in serum α fetoprotein and protein induced by vitamin K antagonist II levels following proton therapy does not necessarily indicate progression of hepatocellular carcinoma

et al. 2019

Self Cite

View full text Add to dashboard Cite

that in the flare-negative group (P=0.015, odds ratio 4.3, 95% confidence interval, 1.3-14.0). In the 23 patients with out-of-field recurrence, the median increase rate of PIVKA-II (203%) was higher than that in the PIVKA-II-flare-positive group (111%, P= 0.035) and the time to recurrence (median, 9 months) was longer than the time to peak AFP level (1 month) in the AFP-flare-positive group (P=0.033). There was no significant association between flares and clinical response. Increases in AFP and PIVKA-II levels following PT should be assessed with caution to avoid misinterpretation of therapeutic outcome.

show abstract

Section: Methodsmentioning

confidence: 99%

Transient increases in serum α fetoprotein and protein induced by vitamin K antagonist II levels following proton therapy does not necessarily indicate progression of hepatocellular carcinoma

et al. 2019

Self Cite

View full text Add to dashboard Cite

show abstract

“…To overcome this issue for the future, hypofractionation is a promising strategy, especially for prostate cancer treatment, based on radiobiological models . In fact, several studies of hypofractionated particle beam RT for prostate cancer have been carried out, and reported the same or lower incidences of adverse events as those seen with conventional photon beam RT using standard fractionation . Further confirmation of the feasibility and efficacy of hypofractionated particle beam RT will enable an increase in patient volume and reduction in the cost per patient.…”

Section: Future Prospectsmentioning

confidence: 99%

“…13 In fact, several studies of hypofractionated particle beam RT for prostate cancer have been carried out, and reported the same or lower incidences of adverse events as those seen with conventional photon beam RT using standard fractionation. 8,21,[38][39][40]54 Further confirmation of the feasibility and efficacy of hypofractionated particle beam RT will enable an increase in patient volume and reduction in the cost per patient. Currently, the JASTRO is carrying out a multi-institutional prospective study of hypofractionated particle beam RT, using PBT for intermediate-risk and CIRT for high-risk prostate cancer.…”

Section: Future Prospectsmentioning

confidence: 99%

Particle therapy for prostate cancer: The past, present and future

et al. 2019

View full text Add to dashboard Cite

Although prostate cancer control using radiotherapy is dose‐dependent, dose–volume effects on late toxicities in organs at risk, such as the rectum and bladder, have been observed. Both protons and carbon ions offer advantageous physical properties for radiotherapy, and create favorable dose distributions using fewer portals compared with photon‐based radiotherapy. Thus, particle beam therapy using protons and carbon ions theoretically seems suitable for dose escalation and reduced risk of toxicity. However, it is difficult to evaluate the superiority of particle beam radiotherapy over photon beam radiotherapy for prostate cancer, as no clinical trials have directly compared the outcomes between the two types of therapy due to the limited number of facilities using particle beam therapy. The Japanese Society for Radiation Oncology organized a joint effort among research groups to establish standardized treatment policies and indications for particle beam therapy according to disease, and multicenter prospective studies have been planned for several common cancers. Clinical trials of proton beam therapy for intermediate‐risk prostate cancer and carbon‐ion therapy for high‐risk prostate cancer have already begun. As particle beam therapy for prostate cancer is covered by the Japanese national health insurance system as of April 2018, and the number of facilities practicing particle beam therapy has increased recently, the number of prostate cancer patients treated with particle beam therapy in Japan is expected to increase drastically. Here, we review the results from studies of particle beam therapy for prostate cancer and discuss future developments in this field.

show abstract

“…This study concluded that young men with prostate cancer continue to have excellent results with respect to 7year biochemical control and 5-year erectile function, without clinically significant urinary incontinence 5 years after proton therapy. 12 In another study (Nakajima K et al, 2018) to evaluate differences in acute toxicity among patients with localized Prostate cancer treated with either conventional fractionated proton therapy (CFPT) or HFPT, a total of 526 eligible patients were analyzed. The patients received 74 gray relative biological effectiveness equivalents [Gy (RBE)]/37 fractions for low-risk patients and 78 Gy (RBE)/39 fractions for intermediate-and high-risk patients in the CFPT group (n = 254) and 60 Gy (RBE)/20 fractions for low-risk and 63 Gy (RBE)/21 fractions for intermediateand high-risk patients in the HFPT group (n = 272).…”

Section: Physics Of Proton Beammentioning

confidence: 99%

“…This study demonstrated the safety of HFPT for localized Prostate cancer patients in terms of acute toxicity. 13…”

Section: Physics Of Proton Beammentioning

confidence: 99%

Proton Beam Therapy for Prostate Cancer: An Overview

Bs¹,

Vats²,

Suhag³

2019

IJTSRD

View full text Add to dashboard Cite

Patients diagnosed with localized prostate cancer have many curative treatment options including several forms of advanced conformal Radiotherapy. Proton radiation is one such radiation treatment modality and, due to its unique physical properties, offers the appealing potential of reduced side effects without sacrificing cancer control. Patients of proton beam therapy (PBT) for prostate cancer had been continuously growing in number due to its promising characteristics of high dose distribution in the tumor target and a sharp distal fall-off. While theoretically beneficial, its clinical values are still being demonstrated from the increasing number of patients treated with proton therapy, from several dozen proton therapy centers around the world. High equipment and facility costs are often the major obstacle for its wider adoption. The picture will be clearer in coming decade as more and more centers throughout the world avail access to this technique and more data emerges on PBT.

show abstract

Acute toxicity of image-guided hypofractionated proton therapy for localized prostate cancer

Abstract: Our results demonstrated the safety of HFPT for localized PCa patients in terms of acute toxicity.

Cited by 29 publications

References 31 publications

Transient increases in serum α fetoprotein and protein induced by vitamin K antagonist II levels following proton therapy does not necessarily indicate progression of hepatocellular carcinoma

Transient increases in serum α fetoprotein and protein induced by vitamin K antagonist II levels following proton therapy does not necessarily indicate progression of hepatocellular carcinoma

Particle therapy for prostate cancer: The past, present and future

Proton Beam Therapy for Prostate Cancer: An Overview

Contact Info

Product

Resources

About